|
1
|
Yoshida Y, Kuramochi A, Ohta A, Furumura
M, Imafuku S, Matsuo M, Chikuda H, Funasaki H, Saito K, Saya H, et
al: Diagnostic criteria and treatment guidelines for nerve fibrosis
type 1 (Recklinghausen's disease). Jpn J Dermatol. 118:1657–1666.
2008.(In Japanese).
|
|
2
|
Wallace MR, Marchuk DA, Andersen LB,
Letcher R, Odeh HM, Saulino AM, Fountain AM, Brereton A, Nicholson
J and Mitchell AL: Type 1 neurofibromatosis gene: Identification of
a large transcript disrupted in three NF1 patients. Science.
249:181–186. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gottfried ON, Viskochil DH and Couldwell
WT: Neurofibromatosis Type 1 and tumorigenesis: Molecular
mechanisms and therapeutic implications. Neurosurg Focus.
28:E82010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Korf BR: Malignancy in neurofibromatosis
type 1. Oncologist. 5:477–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Uusitalo E, Kallionpää RA, Kurki S,
Rantanen M, Pitkäniemi J, Kronqvist P, Härkönen P, Huovinen R,
Carpen O, Pöyhönen M, et al: Breast cancer in neurofibromatosis
type 1: Overrepresentation of unfavourable prognostic factors. Br J
Cancer. 116:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ceccaroni M, Genuardi M, Legge F,
Lucci-Cordisco E, Carrara S, D'Amico F, Greggi S and Scambia G:
BRCA1-related malignancies in a family presenting with von
recklinghausen's disease. Gynecol Oncol. 86:375–378. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American society of clinical oncology/college of
american pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. Arch Pathol Lab Med. 134:907–922. 2010.PubMed/NCBI
|
|
8
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: Assessment of Ki67 in breast cancer: Recommendations from the
international Ki67 in breast cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th.
Wiley-Blackwell; Chichester: 2017
|
|
11
|
Salemis NS, Nakos G, Sambaziotis D and
Gourgiotis S: Breast cancer associated with type 1
neurofibromatosis. Breast Cancer. 17:306–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rasmussen SA and Friedman JM: NF1 gene and
neurofibromatosis 1. Am J Epidemiol. 151:33–40. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takano T, Kawashima T, Yamanouchi Y,
Kitayama K, Ueno K and Hamaguchi H: Genetics of neurofibromatosis 1
in Japan: Mutation rate and paternal age effect. Hum Genetics.
89:281–286. 1992. View Article : Google Scholar
|
|
14
|
Sorensen SA, Mulvihill JJ and Nielsen A:
Long-term follow-up of von Recklinghausen neurofibromatosis.
Survival and malignant neoplasms. N Engl J Med. 314:1010–1015.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zoller ME, Rembeck B, Oden A, Samuelsson M
and Angervall L: Malignant and benign tumors in patients with
neurofibromatosis type 1 in a defined Swedish population. Cancer.
79:2125–2131. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharif S, Moran A, Huson SM, Iddenden R,
Shenton A, Howard E and Evans DG: Women with neurofibromatosis 1
are at a moderately increased risk of developing breast cancer and
should be considered for early screening. J Med Genet. 44:481–484.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Walker L, Thompson D, Easton D, Ponder B,
Ponder M, Frayling I and Baralle D: A prospective study of
neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer.
95:233–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Madanikia SA, Bergner A, Ye X and Blakeley
JO: Increased risk of breast cancer in women with NF1. Am J Med
Genet A. 158a:3056–3060. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakamura M, Tangoku A, Kusanagi H, Oka M
and Suzuki T: Breast cancer associated with Recklinghausen's
disease: Report of a case. Nihon Geka Hokan. 67:3–9.
1998.PubMed/NCBI
|
|
20
|
Murayama Y, Yamamoto Y, Shimojima N,
Takahara T, Kikuchi K, Iida S and Kondo Y: T1 Breast cancer
associated with von recklinghausen's neurofibromatosis. Breast
Cancer. 6:227–230. 1999. View Article : Google Scholar
|
|
21
|
Xu GF, Lin B, Tanaka K, Dunn D, Wood D,
Gesteland R, White R, Weiss R and Tamanoi F: The catalytic domain
of the neurofibromatosis type 1 gene product stimulates ras GTPase
and complements ira mutants of S. cerevisiae. Cell. 63:835–841.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeon YW, Kim RM, Lim ST, Choi HJ and Suh
YJ: Early-onset breast cancer in a family with neurofibromatosis
type 1 associated with a germline mutation in BRCA1. J Breast
Cancer. 18:97–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Campos B, Balmana J, Gardenyes J,
Valenzuela I, Abad O, Fàbregas P, Volpini V and Díez O: Germline
mutations in NF1 and BRCA1 in a family with neurofibromatosis type
1 and early-onset breast cancer. Breast Cancer Res Treat.
139:597–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Daly MB, Pilarski R, Berry M, Buys SS,
Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, et al:
NCCN Guidelines insights: Genetic/familial high-risk assessment:
Breast and ovarian, version 2.2017. J Natl Compr Canc Netw.
15:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
